Circumstantial evidence of a connection between JAM-A, β-catenin, FOXA1 and HER2 in breast cancer patients is presented in Supplemental Table S3, where high mean expression of all four genes correlated with poorer overall survival in HER2-positive and all patients combined, but not in HER2-negative patients. This evidence concerns the gene FOXA1 and breast cancer.